Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of entinostat plus exemestane in advanced or recurrent hormone receptor–positive, HER2-negative breast cancer
jRCT2080223647Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Entinostat + exemestane with Placebo + exemestane (2 arms). Primary endpoint: Progression-free survival (PFS). Started Sep 2017; status: completed.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223647.